Epicyt Pharma reports positive results for BAFA in patient study
Epicyt Pharma has announced positive results from its first-in-human study of BAFA. The study focused on patients who have undergone gastric bypass surgery.
Gothenburg-based Epicyt Pharma AB has announced positive topline results from its Phase 1/2a first-in-human study of BAFA. The biopharmaceutical company develops therapies for impaired intestinal calcium uptake.
The study focused on patients who have undergone gastric bypass surgery, a group often experiencing calcium deficiency due to post-surgical intestinal changes. The development of BAFA aims to improve the quality of life for these patients.
"The results provide a strong foundation for further research," said Epicyt Pharma AB CEO Jane Doe. Detailed findings from the study will be presented at upcoming scientific conferences and in publications.
The pharmaceutical company is continuing to advance its clinical program and other drug candidates, aiming to bring new treatments to patients with nutritional deficiencies.